The Business Brew
Bill Brewster
Welcome to The Business Brew
This podcast’s mission is to dig deep into the thought patterns and analysis of investors and business people. The podcast stemmed from Bill Brewster consistently feeling like he was listening to prepackaged material while listening to podcasts. Instead, he wanted long form, in depth, discussions about finance, capital allocation, and the psychology of investing/business.
We are interested in interviewing portfolio managers, Wall Street sell side analysts, buy side analysts, private investors, owner operators, and anyone that is willing to go in depth about running a company/division. So, if you are interested in participating please email us with the subject “Guest Appearance.”
Disclaimer: This podcast is for informational and educational purposes only. Nothing in this podcast is investment advice. All information in this is opinion based, potentially biased, and requires verification.
Bill and his guests make no representation, warranty or undertaking, express or implied, as to the accuracy, reliability, completeness or reasonableness of the information contained in these podcasts. Any assumptions, opinions and estimates expressed constitute the participant’s judgment as of the date thereof and are subject to change without notice. Any projections contained in the information are based on a number of assumptions as to market conditions and there can be no guarantee that any projected outcomes will be achieved. This podcast does not accept any liability for any direct, consequential or other loss arising from reliance on the contents of this presentation.
This podcast series DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICIATION OF AN OFFER TO BUY ANY SECURITIES MENTIONED OR DISCUSSED. Seek the your financial, tax, legal, accounting, or other advisor’s advice before making any investment decisions. We are not your fiduciary or advisor.
This podcast’s mission is to dig deep into the thought patterns and analysis of investors and business people. The podcast stemmed from Bill Brewster consistently feeling like he was listening to prepackaged material while listening to podcasts. Instead, he wanted long form, in depth, discussions about finance, capital allocation, and the psychology of investing/business.
We are interested in interviewing portfolio managers, Wall Street sell side analysts, buy side analysts, private investors, owner operators, and anyone that is willing to go in depth about running a company/division. So, if you are interested in participating please email us with the subject “Guest Appearance.”
Disclaimer: This podcast is for informational and educational purposes only. Nothing in this podcast is investment advice. All information in this is opinion based, potentially biased, and requires verification.
Bill and his guests make no representation, warranty or undertaking, express or implied, as to the accuracy, reliability, completeness or reasonableness of the information contained in these podcasts. Any assumptions, opinions and estimates expressed constitute the participant’s judgment as of the date thereof and are subject to change without notice. Any projections contained in the information are based on a number of assumptions as to market conditions and there can be no guarantee that any projected outcomes will be achieved. This podcast does not accept any liability for any direct, consequential or other loss arising from reliance on the contents of this presentation.
This podcast series DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICIATION OF AN OFFER TO BUY ANY SECURITIES MENTIONED OR DISCUSSED. Seek the your financial, tax, legal, accounting, or other advisor’s advice before making any investment decisions. We are not your fiduciary or advisor.
Episodes
Mentioned books
May 7, 2026 • 1h 21min
Another FDA vs uniQure Episode
Peter Mantas, investor and biotech commentator who reported from the H‑I conference, returns to discuss FDA regulation and patient advocacy. He recounts conference mood, clinician and patient reactions, and debates ethics of placebo neurosurgery. They cover AMT‑130’s mechanism, biomarker timing, global approvals, and how regulators and cost frameworks shape access and biotech investment.
Apr 30, 2026 • 1h 32min
Revisiting Fairfax Financial
Charles Frischer, a long‑time Fairfax shareholder and multi‑family real estate investor, and Asheef Lalani, a CIO and CFA with deep insurance and accounting expertise, return with an update. They recap an upbeat annual meeting, discuss Fairfax’s conservative reserving, leverage and capital allocation mechanics, hidden balance sheet value, buybacks and TRS dynamics, succession planning, and why volatility creates compounding opportunities.
Apr 24, 2026 • 1h 38min
Evan Tindell
Evan Tindell, CIO at Bireme Capital and market letter writer, shares his current market stance and reflections on past mistakes. Conversations jump from cheaper foreign equities and Japan-focused SaaS durability to software deratings, AI’s real effects, and stock-picking over allocation. Complex corporate structures, short ideas, and patience in discounted NAV plays also come up.
14 snips
Mar 26, 2026 • 1h 12min
Sonu Chawla - Managing Mid Cap Exposure - $TSCM
Sonu Chawla, portfolio manager and partner at Times Square Capital with a tech and math background and an MBA from Kellogg. She discusses valuation discipline and assessing management. She talks mid-cap advantages, barbell portfolios of secular winners and cyclicals, and sector calls from software to materials and energy. Short, focused conversations on navigating market dislocations and spotting mid-cap opportunities.
11 snips
Mar 21, 2026 • 1h 51min
Notes From The Beauty Contest
Crash Kilnikov, Substack author of Notes From The Beauty Contest and former buy‑side healthcare analyst, joins to discuss deep dives on undercovered large caps. He explains Regeneron’s mice antibody platform, rapid COVID response, and founder influence. He also talks about BMW’s EV strategy, cost saves, and hidden Rolls‑Royce value. Conversations cover research process, margin stories, and why contrarian ideas attract him.
Mar 6, 2026 • 1h 35min
Current Events - uniQure and the FDA
Professor Sarah Tabrizi, neurologist and Huntington's researcher, and Dr. Victor Sung, clinician-researcher on AMT-130, discuss AMT-130 gene therapy delivery and trial design. They debate use of EnrollHD as a propensity-matched external control, surgical and imaging details, ethical issues around long blinding, FDA skepticism, and regulatory pathways.
26 snips
Mar 6, 2026 • 1h 3min
Jacob Shapiro - A "Geopolitical Cousin" Joins the Show
Jacob Shapiro, a geopolitical analyst who advises investors and companies, joins to explore geopolitics' ripple effects. He discusses food-supply consolidation and agriculture investing. He reevaluates Iran and the risks of prolonged conflict. He examines Mexico beyond cartels, multipolarity versus U.S. policy shifts, and future threats from AI and WMD proliferation.
39 snips
Feb 13, 2026 • 1h 26min
Investing Unscripted
Jason, co-host known for conversational takes on portfolio construction, and Jeff, long-form investor focused on stock ideas and psychology, drop in for lively investing banter. They talk unscripted formats, AI assistants and everyday glitches. Conversations jump from Zoom’s market story to buybacks, variable dividends in commodities, consumer stock challenges, and healthcare opportunities tied to aging demographics.
29 snips
Feb 6, 2026 • 1h 22min
Adam Wilk
Adam Wilk, Founder and CIO of Greystone Capital Partners and former NBA scout and commercial underwriter, shares his investment approach. He describes scouting-informed decision-making, how culture and systems build durable advantages, the research value of scuttlebutt conversations, why small caps offer mispricings, and company cases like Shift4 and Duolingo illustrating path-dependent moats.
18 snips
Feb 1, 2026 • 25min
Paying It Forward
Reflections on family alcohol patterns and a personal health wake-up. A 30-day clean-eating and sober challenge that led to weight loss, more energy, and better relationships. The power of accountability and practical rules for staying on track. An open offer to be an accountability buddy for 28 days to help listeners start their own momentum.
